A retrospective Chinese study finds that adding the PD-1 inhibitor tislelizumab to paclitaxel-carboplatin chemotherapy and ...

Oncolytics Biotech stock was last at USD 0.63 on October 2, 2026, as REO 033 advanced toward year-end interim data. Six-month ...

Genmab has reported data from Part C of the Phase I/II RAINFOL-01 trial of rinatabart sesutecan (Rina-S; GEN1184) in patients with platinum-resistant ovarian cancer.

The inspection covered 214 pharmacies attached to medical colleges and private hospitals. Of 130 medicines analysed, the ...

A case report describes a 57-year-old woman with a giant intrapulmonary solitary fibrous tumour exceeding 16 centimetres, ...

A 38-year-old ex-soldier is selling the wheelchair-accessible home he and his wife spent £150,000 adapting now his brain ...

New York, NY, Oct. 05, 2026 (GLOBE NEWSWIRE)-- The Icahn School of Medicine at Mount Sinai will award its 2026 Yergin Family International Prize for Biomedical Research to Napoleone Ferrara, MD, ...

Summit Therapeutics Inc. ( NASDAQ: SMMT) today announced the successful closing of AstraZeneca’s (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued ...

Genmab has linked an antibody-drug conjugate (ADC) to median progression-free survival (PFS) of 9.5 months, leading TD Cowen ...

Noticing he lost hearing in one ear in 2012, Paul Coleman, 38, was diagnosed with a benign brain tumour, which was monitored with annual MRI scans. Having lived a ‘normal life’ for several years, he ...

An inspection by the Uttar Pradesh Food Safety and Drug Administration (UPFSDA) has found a staggering gap between the ...

Overall survival (OS): Estimated survival was 48% at both two and three years. Median OS was 14.8 months. Objective response rate (ORR): 23% of patients (8/35) had a response, including one complete ...